Mark Prausnitz


Mark

 

Prausnitz

Regents' Professor
Primary School/Department: 
Georgia Tech School of Chemical and Biomolecular Engineering
Title 2: 
J. Erskine Love Jr. Chair in Chemical & Biomolecular Engineering
Title 3: 
Director of the Center for Drug Design, Development and Delivery

Phone: 
404-894-5135
Office Location: 
IBB 1312
University: 
Georgia Institute of Technology

Research Affiliations:

Research Center Affiliations: 
Regenerative Engineering and Medicine (REM)
Nanomedicine Center for Nucleoprotein Machines
Integrated Cancer Research Center
Immunoengineering
Center for ImmunoEngineering
Center for Drug Design Development & Delivery

Research Areas:

Research Areas: 
Cancer Biology
Drug Design, Development and Delivery

Research Interests:

  • Develop microneedle patches for vaccination that is simpler and more effective than conventional injection.
  • Design microneedle patches for rapid and slow-release delivery of drugs.
  • Translate microneedle technology from the laboratory into human clinical studies and advanced manufacturing.
  • Study targeted drug delivery to the eye using microneedle injection into the suprachoroidal space.
  • Examine the effects of laser-activated nanoparticles on delivery of molecules into cells to manipulate cellular behavior

Dr. Prausnitz and his colleagues carry out research on biophysical methods of drug delivery, which employ microneedles, ultrasound, lasers, electric fields, heat, convective forces and other physical means to control the transport of drugs, proteins, genes and vaccines into and within the body. A major area of focus involves the use of microneedle patches to administer vaccines to the skin in a painless, minimally invasive manner that improves vaccine effectiveness by targeting delivery to the skin’s immune cells. In collaboration with Emory University, the Centers for Disease Control and Prevention and other organizations, Dr. Prausnitz’s group is advancing microneedles from device design and fabrication through pharmaceutical formulation and preclinical animal studies through studies in human subjects. In addition to developing a self-administered influenza vaccine using microneedles, Dr. Prausnitz is translating microneedles technology especially to make vaccination in developing countries more effective.